[Clinical evaluation of ciclobendazole (C-C 2481) in the treatment of colonic helminth diseases].
A total of 105 patients with mild helminthiases have been treated with ciclobendazole, a benzimidazole derivative related to mebendazole. The treatment lasted 3 days. A group of 74 patients received 200 mg/day ciclobendazole while another 31 patients were given double this dose. The excretion rates achieved were very high at 84.2 and 83.3% respectively in trichuriasis and 93.3 and 100% respectively in ascariasis. In a relatively small number of cases of ankylostomiasis, the values were, however, considerable lower (38.5 and 20.0% respectively). Since ciclobendazole is well tolerated, there is a need for studies with higher dosages and possibly also long-term studies.
D000328:Adult; D001562:Benzimidazoles / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003108:Colonic Diseases / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005243:Feces / Q000469:parasitology; D005260:Female; D006373:Helminthiasis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010270:Parasite Egg Count
D001562:Benzimidazoles
Klinische Bewertung von Ciclobendazol (C-C 2481) bei der Behandlung von Wurmerkrankungen des Darmes.